What's in H. Lundbeck A/S's pipeline?

H. Lundbeck A/S has 44 drugs in our index: 5 marketed, 0 filed, 6 in Phase 3, 7 in Phase 2, 26 in Phase 1.

Which companies overlap with H. Lundbeck A/S's portfolio?

Top competitors by shared drug class: University of North Carolina, Chapel Hill, Acacia Pharma Ltd, AstraZeneca, Shanghai Mental Health Center, Alameda Health System.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/h-lundbeck-a-s.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

H. Lundbeck A/S — Portfolio Competitive Intelligence Brief

H. Lundbeck A/S pipeline: 5 marketed, 0 filed, 6 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 6 Phase 3 7 Phase 2 26 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Zerdol	SERTINDOLE	marketed	sertindole	5-hydroxytryptamine receptor 2C	Neuroscience	1996-01-01
Memantine (twice daily)	Memantine (twice daily)	marketed	NMDA receptor antagonist	NMDA receptor	Neurology
Memantine (once daily)	Memantine (once daily)	marketed	NMDA receptor antagonist	NMDA receptor	Neurology
Azilect®	Azilect®	marketed
Droxidopa capsules	Droxidopa capsules	marketed
Aripiprazole and aripiprazole once-monthly	Aripiprazole and aripiprazole once-monthly	phase 3	Atypical antipsychotic	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin 5-HT2A receptor (antagonist)	Psychiatry
MK0928, gaboxadol	MK0928, gaboxadol	phase 3	GABA-A receptor agonist	GABA-A receptor (delta subunit-containing)	Neurology / Sleep Medicine
Adjunct brexpiprazole	Adjunct brexpiprazole	phase 3	Serotonin-dopamine activity modulator (SDAM)	Dopamine D2 receptor, Serotonin 5-HT1A receptor	Psychiatry
Paliperidone and paliperidone palmitate	Paliperidone and paliperidone palmitate	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor	Psychiatry/Neurology
Vortioxetine (Lu AA21004)	Vortioxetine (Lu AA21004)	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter	Psychiatry
Lu AA21004	Lu AA21004	phase 3	Multimodal antidepressant; serotonin reuptake inhibitor with 5-HT1A agonist and 5-HT7 antagonist activity	Serotonin transporter (SERT), 5-HT1A receptor, 5-HT7 receptor	Psychiatry/Neurology

Therapeutic area mix

Neurology · 3
Psychiatry · 3
Psychiatry/Neurology · 2
Neurology / Sleep Medicine · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University of North Carolina, Chapel Hill · 2 shared drug classes
Acacia Pharma Ltd · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Shanghai Mental Health Center · 2 shared drug classes
Alameda Health System · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Aclaris Therapeutics, Inc. · 1 shared drug class
Ajou University School of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for H. Lundbeck A/S:

Cite this brief

Drug Landscape (2026). H. Lundbeck A/S — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/h-lundbeck-a-s. Accessed 2026-05-16.